Nucleotides for the treatment of cancer

Patent metadata

Field	Value
Publication number	US-10815264-B2
Application number	US-201615576607-A
Country	US
Kind code	B2
Filing date	May 25, 2016
Priority date	May 27, 2015
Publication date	Oct 27, 2020
Grant date	Oct 27, 2020

Abstract

The present application relates to novel nucleoside derivatives of formula (I) as claimed in claim 1, pharmaceutical compositions comprising the compounds, processes of preparation thereof, and methods of use thereof for treating cancer.

First claim

The invention claimed is:

1. A compound according to Formula I:

or a pharmaceutically acceptable salt thereof, wherein:
one of R 1 and R 2 is hydrogen and the other is

or R 1 and R 2 together with the two oxygen atoms to which they are attached form the ring structure:

R 3 is hydrogen, C 1-10 alkyl, C 2-11 alkenyl, C 2-11 alkynyl, C 1-10 alkoxycarbonylC 1-10 alkyl, C 1-10 alkylcarbonylthioC 1-10 alkyl, C 1-10 alkyldisulfideC 1-6 alkyl, aryl, or heteroarylC 1-10 alkyl, wherein alkyl is optionally substituted by one, two, or three substituents independently selected from halogen and hydroxy, and heteroaryl is substituted by one or two substituents selected from C 1-10 alkyl and nitro;
R 4 is hydrogen or C 1-10 alkyl;
R 5 is C 1-10 alkoxycarbonyl, C 3-10 cycloalkoxycarbonyl, C 1-10 alkylcarbonyloxyC 1-10 alkyl, C 3-10 cycloalkylcarbonyoxy, aryl, aryloxy, C 1-10 alkylaryl, arylC 1-10 alkyl, arylC 1-10 alkoxycarbonyl, aryloxycarbonyl, heteroaryl, heteroarylC 1-10 alkyl, or C 1-10 alkylheteroaryl;
R 6 is

and
W is O or S,
providing that the compounds of the following formula are excluded:

wherein R 3′ is aryl or an optionally substituted heteroaryl, R 4′ is C 1-10 alkyl, R x is C 1-6 alkyl, C 3-10 cycloalkyl, arylC 1-10 alkyl or aryl, and W is O.

2. The compound of claim 1 , wherein R 1 and R 2 together with the two oxygen atoms to which they are attached form the ring structure:

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , wherein the compound has a formula II:

or a pharmaceutically acceptable salt thereof,
providing that the compounds of the following formula are excluded:

wherein R 3 is aryl or an optionally substituted heteroaryl, R 4 is C 1-10 alkyl, R x is C 1-6 alkyl, C 3-10 cycloalkyl, arylC 1-10 alkyl or aryl, and W is O or S.

4. The compound of claim 1 , wherein the compound has a formula IV:

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 , wherein W is O.

6. The compound of claim 1 , wherein the compound is selected from:

or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.

8. A method for the treatment of a cancer comprising administering an effective treatment amount of a compound according to Formula I:

or a pharmaceutically acceptable salt thereof, wherein:
one of R 1 and R 2 is hydrogen and the other is

or R 1 and R 2 together with the two oxygen atoms to which they are attached form the ring structure:

R 3 is hydrogen, C 1-10 alkyl, C 2-11 alkoxycarbonylC 2-11 alkyl, C 1-10 alkylcarbonylthioC 1-10 alkyl, C 1-10 alkyldisulfideC 1-6 alkyl, aryl or heteroarylC 1-10 alkyl, wherein alkyl is optionally substituted by one, two, or three substituents independently selected from halogen and hydroxy, and heteroaryl is substituted by one or two substituents selected from C 1-10 alkyl and nitro, provided that both occurrences of R 3 , when present, are not simultaneously hydrogen;
R 4 is hydrogen or C 1-10 alkyl;
R 5 is C 1-10 alkoxycarbonyl, C 3-10 cycloalkoxycarbonyl, C 1-10 alkylcarbonyloxyC 1-10 alkyl, C 3-10 cycloalkylcarbonyoxy, aryl, aryloxy, C 1-10 alkylaryl, arylC 1-10 alkyl, arylC 1-10 alkoxycarbonyl, aryloxycarbonyl, heteroaryl, heteroarylC 1-10 alkyl, or C 1-10 alkylheteroaryl;
R 6 is

and
W is O or S,
providing that the compounds of the following formula are excluded:

wherein R 3′ is aryl or an optionally substituted heteroaryl, R 4′ is C 1-10 alkyl, R x is C 1-6 alkyl, C 3-10 cycloalkyl, arylC 1-10 alkyl or aryl, and W is O, or a pharmaceutically acceptable salt thereof.

9. The method of claim 8 , wherein said compound or composition is administered in combination with one or more other therapeutic agents.

10. A combination comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and one, two, three, or more other therapeutic agents.

Assignees

• Idenix Pharmaceuticals Llc
• Southern Res Inst
• Dousson Cyril B
• Dukhan David
• Paparin Jean Laurent
• Parsy Christophe C

Inventors

• Dousson Cyril B
• Dukhan David
• Paparin Jean-Laurent
• Parsy Christophe C

Classifications

• A61K2121/00

  Preparations for use in therapy · CPC title

• C07H19/10

  with the saccharide radical esterified by phosphoric or polyphosphoric acids · CPC title

• A61P35/02

  specific for leukemia · CPC title

• C07H19/11 Primary

  containing cyclic phosphate · CPC title

• C07D409/04

  directly linked by a ring-member-to-ring-member bond · CPC title